Your Testosterone Doesn't Have to Decline With Age @BarbellMedicine

Uploaded May 2026 | Updated September 2026, 2 weeks ago

Longitudinal data shows that men who remain lean, active, and free of chronic disease maintain stable testosterone levels well into their 70s and 80s.

The decline tracks with metabolic health, not your birth year. It is not destiny.

From Episode 1 of the Signal launch series on the Barbell Medicine Podcast.

From Episode 1 of the Signal launch series on the Barbell Medicine Podcast.

Full episode: youtube.com/watch?v=dm5FxIw-I7Y
#testosterone #aging #menshealth #longevity #barbellmedicine

Your Testosterone Doesnt Have to Decline With Age

My body, my choice.” Fine. But consent has to be informed.

Who Needs Testosterone, and Whos Not Getting It I Signal Episode 4

Half of low T results normalize on repeat

Same genes, two environments, ten times the obesity

If youve regained the weight, watch this

Does HIIT Impact Power and Strength Production

$My Body My Choice? The Problem With Buying Unproven Peptides “My body, my choice” is the argument for buying these peptides, and this segment takes it seriously before showing where it breaks. It covers what informed consent actually requires, what the courts have said, and then the part most people came for: what actually works for a stubborn tendon, and what would change my mind on BPC-157. Timestamps: 00:00 Both sides of the scale are blank 00:22 My body, my choice and informed consent 01:14 Abigail Alliance and United States v. Rutherford 01:57 What Right to Try actually covers 02:38 Oral capsules and WADA status 02:59 What actually works for a tendon 03:37 Cortisone, PRP, and loading 04:33 What would change my mind 05:13 The verdict 06:09 What is coming in February 2027 Resources: Barbell Medicine coaching and templates: https://www.barbellmedicine.com Plus podcast subscription: https://www.barbellmedicine.com/shop/subscriptions/plus-podcast-subscription/ Barbell Medicine Premium: https://www.barbellmedicine.com/shop/subscriptions/barbell-medicine-premium/ Signal (now shipping): https://www.barbellmedicine.com/shop/learning/signal/ References: 1. FDA. PCAC briefing document. Jul 23-24, 2026. 2. FDA. BPC-157 bulk substance review. PCAC 2026. fda.gov/media/193343 3. FDA. TB-500 bulk substance review. PCAC 2026. Media 193349. 4. FDA. KPV, MOTS-c, Semax, Epitalon, Emideltide reviews. 2026. 5. FDA. Questions for the PCAC. Jul 2026. 6. FDA. PCAC roster 2026. Media 193772. 7. FDA. PCAC roster 2022. Media 159040. 8. openFDA. FAERS reports, BPC-157. open.fda.gov 9. 21 CFR 216.23 (2026). 10. FD&C Act 503A; 21 USC 353a. 11. Abigail Alliance v von Eschenbach, 495 F3d 695 (DC Cir 2007). 12. US v Rutherford, 442 US 544 (1979). 13. Right to Try Act of 2017, Pub L 115-176. 14. FDA. Peptide drug products. Draft guidance, 2020. 15. Ruenzi. PL 14736 (BPC 157) in ulcerative colitis. Gastroenterology 2005; abstract only. 16. Staresinic. BPC 157, transected rat quadriceps. J Orthop Res 2006;24:1109. 17. Gwyer. BPC 157 and soft tissue healing. Cell Tissue Res 2019;377:153. 18. Sikiric. BPC 157, hemorrhage/thrombosis. Pharmaceuticals 2026;19:463. 19. Stavchansky. Glyprolines and gene expression, Semax. Genes 2022;13:2380. 20. Mendias. Approved and unapproved peptides. Sports Med 2026. 21. Moseley. Arthroscopic surgery for knee OA. NEJM 2002;347:81. 22. Cobb. Internal mammary ligation, double-blind. NEJM 1959;260:1115. 23. Dimond. IMA ligation vs sham for angina. Am J Cardiol 1960;5:483. 24. Alfredson. Eccentric calf training, Achilles tendinosis. AJSM 1998;26:360. 25. Kongsgaard. Steroid vs exercise, patellar tendinopathy. Scand J Med Sci Sports 2009;19:790. 26. Langberg. Peritendinous metabolism during exercise. J Physiol 1999;515:919. 27. Coombes. Steroid vs physiotherapy, tennis elbow. JAMA 2013;309:461. 28. Kearney. PRP vs sham, Achilles tendinopathy. JAMA 2021;326:137. 29. Pavlova. Exercise dose in tendinopathy, meta-analysis. BJSM 2023;57:1327. 30. Weintraub. Fen-phen vs placebo. Clin Pharmacol Ther 1992;51:586. 31. Connolly. Valvular heart disease with fen-phen. NEJM 1997;337:581. 32. CDC. Valvulopathy with fenfluramine. MMWR 1997;46:1061. 33. Bombardier. VIGOR: rofecoxib vs naproxen. NEJM 2000;343:1520. 34. Graham. MI and sudden death, COX-2 inhibitors. Lancet 2005;365:475. 35. Smith. Fungal infections, contaminated methylprednisolone. NEJM 2013;369:1598. 36. Adunsky. MK-0677 after hip fracture. Arch Gerontol Geriatr 2011;53:183. Halted early, CHF signal. 37. Nass. Oral ghrelin mimetic in older adults. Ann Intern Med 2008;149:601. 38. Van Wagoner. Composition of SARMs sold online. JAMA 2017;318:2004. 39. ECRI/ISMP. Unapproved peptide products. Apr 2026. 40. CSPI. Are injectable peptides safe? cspinet.org 41. WADA. 2026 Prohibited List. wada-ama.org 42. USADA. BPC-157: a prohibited peptide. usada.org 43. Time. FDA panel backs compounding peptides. Jul 2026. 44. RAPS. Committee backs controversial peptides. 2026. 45. STAT. Panel okays peptides for compounding. Jul 2026. 46. NBC News. Panel eases peptide limits over FDA objections. 2026. 47. AP. Financial ties among FDA peptide panel members. 2026. 48. Leerink. PCAC vote and telehealth compounding market. 2026. 49. Examine.com. BPC-157 research breakdown. examine.com/supplements/bpc-157/ 50. Jarry. BPC: no proof required. McGill OSS. mcgill.ca/oss$

Why “5 Pounds of Muscle in 8 Weeks” Is Probably Water

The Womens Health Initiative 20 Years Later